Jun. 23 at 11:30 PM
$AIM How can the company succeed with a Phase 3 “if the company can’t access warrant proceeds or other funding sources.”? The key is the phrase “or other funding sources” — a phrase which disappears from consideration when Equels repeatedly reverts to dilution and reverse splits, massively damaging shareholders over and over.
Other funding sources should include
(1) licensing arrangements or other collaboration with major drug companies, (of which they have done some but too little), (2) grants and support from major government agencies, of which there are many, and (3) investment from large market funds like Vanguard, which have significantly diminished their holdings because of bad management.
